Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | TNKS | O95271 | 4/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979269 | 0.87 | USP30 (0.50) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL17714087 | 0.81 | MEN1 (0.54) | GPR119KMT2AUSP30RET | |
| SCHEMBL438489 | 0.81 | TNKS (0.48) | TNKSTNKS2KMT2APARP1 | |
| SCHEMBL18228469 | 0.79 | GPR119 (0.58) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL32661690 | 0.79 | GPR119 (0.56) | GPR119HPGDKMT2AUSP30RET | |
| SCHEMBL441012 | 0.79 | KDM4E (0.62) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL21605851 | 0.78 | GPR119 (0.55) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL408202 | 0.78 | GPR119 (0.63) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL9980847 | 0.78 | KMT2A (0.58) | GPR119HPGDPTPN2PTPN1PTPN6 | |
| SCHEMBL14113587 | 0.77 | KMT2A (0.71) | GPR119HPGDPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-11 | — | — | US | disclosed |
| EP-3512857-B1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3512857-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceutica NV (BE) | 2019-07-24 | — | — | EP | disclosed |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-11 | — | — | US | disclosed |
| WO-2018050686-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220517-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | GPR119 752/4885HPGD 1535/4885PTPN2 3237/4885 |
| US-20190211036-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, MEN1 | GPR119 1004/4885HPGD 1558/4885PTPN2 3129/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | GPR119 40/4885HPGD 1034/4885PTPN2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.